Stephen H Leech MD Ph.D., F.R.C.P.
Clinical & Laboratory Immunology
retired
Join to View Full Profile
3401 N Broad St2nd FloorPhiladelphia, PA 19140
Phone+1 215-707-4353
Fax+1 215-707-2781
Dr. Leech is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Stephen Leech is an Immunologist based in Philadelphia, PA,. He earned his medical degree from the University of Edinburgh Medical School in 1965 and completed an internship at the University of Tennessee Medical Center and a residency in Internal Medicine at the Mayo Clinic College of Medicine and Science. Dr. Leech was awarded a Ph.D. for his research in Immunology at University College London, UK in 1976. He has published several research articles, notably on topics such as renal & cardiac transplantation. His major contribution has been in the early recognition and treatment of antibody-mediated rejection of the human heart allograft.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1967 - 1969
University of Tennessee Medical Center at KnoxvilleInternship, Transitional Year, 1966 - 1967
University of Edinburg Medical SchoolClass of 1965
Certifications & Licensure
PA State Medical License 1993 - 2012
American Board of Allergy and Immunology Allergy & Immunology
Publications & Presentations
PubMed
- 9 citationsOutcomes of Renal Transplantation in Older High Risk Recipients: Is There an Age Effect?Andreas Karachristos, Argenis Herrera, Nicole M. Sifontis, Justin Darrah, Craig Baribault
The Journal of Surgical Research. 2010-06-15 - 1 citationsTargeting alloantibody production with bortezomib: does it make more sense?Iris J. Lee, Serban Constantinescu, Avrum Gillespie, Swati Rao, Patricio Silva
Clinical Transplants. 2010-01-01 - 1 citationsBortezomib as therapy for mixed humoral and cellular rejection: should it be first line?Iris J. Lee, Serban Constantinescu, Avrum Gillespie, Abhishek Swami, Mark Birkenbach
Clinical Transplants. 2009-01-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
